Compass Earnings Reports

Compass Therapeutics reported a net loss of $19.9 million for Q2 2025, or $0.14 per share, compared to a net loss of $13.1 million, or $0.10 per share, for the same period in 2024. The company ended the quarter with $101 million in cash and marketable securities, providing a cash runway into 2027. Research and Development expenses increased significantly due to additional manufacturing expenses for key drug candidates.

Compass Therapeutics, Inc. reported a net loss of $16.633 million for the first quarter of 2025, an increase from the $10.787 million net loss in the same period last year. The company's cash and cash equivalents decreased to $41.048 million, and total assets were $131.451 million. Research and development expenses increased significantly, primarily due to manufacturing expenses for tovecimig and a new program, CTX-10726.

Compass Therapeutics reported a net loss of $10.8 million for the first quarter of 2024. The company's cash and marketable securities were $156.3 million as of March 31, 2024, extending the cash runway into late 2026.

Compass Therapeutics reported a net loss of $42.5 million for the year ended December 31, 2023, and ended the year with $152.5 million in cash and marketable securities, extending the cash runway into mid-2026. The company is focused on clinical development of CTX-009 and expects to report top-line data from Phase 2 trials by mid and end of the year.

Compass Therapeutics reported a net loss of $10.0 million for the third quarter of 2023, with R&D expenses at $8.8 million and G&A expenses at $3.1 million. The company's cash and marketable securities were $164 million as of September 30, 2023.

Compass Therapeutics reported a net loss of $11.3 million for the second quarter of 2023, with R&D expenses increasing due to higher spending on CTX-009. The company's cash and marketable securities were $169 million as of June 30, 2023, providing a cash runway into 2026.

Compass Therapeutics reported a net loss of $7.8 million for the first quarter of 2023. The company's cash and marketable securities were $175 million as of March 31, 2023, providing an anticipated cash runway into 2026.